Galapagos
🇧🇪Belgium
- Country
- 🇧🇪Belgium
- Ownership
- Public
- Established
- 1999-01-01
- Employees
- 1.1K
- Market Cap
- $1.9B
- Website
- http://www.glpg.com
- Introduction
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.
GLPG0259 Solid Formulation Bioavailability and Food Effect
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: GLPG0259Drug: GLPG0259 solution
- First Posted Date
- 2009-12-02
- Last Posted Date
- 2010-04-27
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 12
- Registration Number
- NCT01024517
- Locations
- 🇧🇪
SGS Stuivenberg, Antwerp, Belgium
GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy Subjects
- First Posted Date
- 2009-10-05
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 24
- Registration Number
- NCT00989703
- Locations
- 🇧🇪
SGS Stuivenberg, Antwerp, Belgium
First-in-Human Single Ascending Subcutaneous (s.c.) Dose and Single Oral Dose of GLPG0187
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: GLPG0187Drug: Placebo
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2010-01-15
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 18
- Registration Number
- NCT00928343
- Locations
- 🇧🇪
SGS Stuivenberg, Antwerp, Belgium
First-in-Human Single Ascending and Multiple Dose of GLPG0259
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: placeboDrug: GLPG0259
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- Galapagos NV
- Target Recruit Count
- 32
- Registration Number
- NCT00905138
- Locations
- 🇧🇪
SGS Stuivenberg, Antwerp, Belgium
© Copyright 2025. All Rights Reserved by MedPath